Posts Tagged ‘Aricept’

Drug Helps Brain Grow New Cells

Tuesday, August 24th, 2010

Researchers have found a drug that can help the brain grow new cells, and they said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Center in Dallas who worked on the study, said in a telephone interview. “What our compound does is allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation and Pfizer experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them, and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.wpgauto.com/

Wpg Auto site

Quality Inn Winnipeg Extended Stay Hotel

Canadian  Fleet

Derrick Dodge

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • No Waiting for the Stem Cell Research Debate To Finish While the debate on stem cell research rages on, Donald Cecil couldn’t afford to wait for research. Donald badly needed treatment for his heart which was damaged by a series...
  • Brain On Overdrive Throughout this pregnancy I have been a bit cautious. Especially since I know what it's like to suffer a miscarriage, I think that somewhat put a damper on my excitement,...
  • Can Cars Run On Water? Dear EarthTalk: I’ve heard that cars can be modified to run on water. How is this possible? There are a number of online marketing offers of kits that will convert...
  • Microsoft and Firefox engineering a Chrome web OS rival? In July, Google Inc. had announced that it was working on an operating system for netbooks called Chrome operating system (OS) and it is reported that it is set to...
  • Skin cells transform to liver cells In a fresh demonstration of science's newfound ability to alter the basic units of human life, researchers at the Medical College of Wisconsin have turned the cells in human skin...
  • Judge stops federal funding of embryonic stem cell research [/caption] Washington -- A U.S. district judge granted a preliminary injunction Monday to stop federal funding of embryonic stem cell research that he said destroys embryos, ruling it went against...
  • The Business of Blogging One of the main problems facing corporate bloggers is that they do not treat their blogs like a business, and they may not take them seriously enough. There are fortunes...

A pill to make you smarter? Drug grows brain cells

Tuesday, August 10th, 2010

Researchers have found a drug that can help the brain grow new cells and said their study may lead to ways to improve experimental Alzheimer’s drugs.

The researchers’ work, done on rodents, builds on findings that all mammals, including humans, make brain cells throughout their lives. Most of these die, but this drug helps more of the baby cells survive and grow to become functioning brain cells.

“We make new neurons every day in our brain,” Andrew Pieper of the University of Texas Southwestern Medical Centre in Dallas who worked on the study, said in a telephone interview. “What our compound does in allow more of them to survive.”

The compound is called P7C3 for now, and the researchers have already started tweaking it to make it more effective. They said it seems safe and appears to work even when taken as a pill.

The compound is similar to Medivation Inc (MDVN.O) and Pfizer Inc’s (PFE.N) experimental Alzheimer’s drug, Dimebon, and may provide ways to improve its effects, Pieper and colleagues reported in the journal Cell.

It is also similar to some compounds owned by Serono, the researchers said.

Dimebon, originally a Russian-made antihistamine also known as latrepirdine, failed in a clinical trial for Alzheimer’s disease in March.

“For the sake of patients suffering from Alzheimer’s disease, it is hoped that the apparently marginal clinical utility of Dimebon might be enhanced by improvements in both its potency and ceiling of proneurogenic, neuroprotective efficacy,” the researchers wrote.

“If so, our work offers concrete assays for the development of improved versions of these neuroprotective drugs.”

Alzheimer’s gradually destroys the brain and affects 26 million people globally. Drugs, such as Pfizer’s Aricept, improve symptoms only minimally.

OLD RATS, NEW TRICKS

The researchers went through 1,000 representative compounds from 300,000 chemicals, pooled them and administered them to mice. They then dissected the brains to see whether any of the mice had made new cells in the hippocampus, a region of the brain associated with learning and memory.

They eventually narrowed the field to P7C3.

When they gave it to old rats for two months, the elderly rodents did far better than other old rats in learning their way around a water maze.

When dissected, the treated rats turned out to have three times the usual number of newborn neurons in a brain region called the dentate gyrus.

They made a derivative of P7C3 called A20 that worked even better.

When the researchers tested Dimebon and the Serono compounds, they found these drugs also stimulated the growth of new brain cells. Being able to target their effects could lead to better drugs to treat Alzheimer’s and perhaps other diseases that destroy brain cells like strokes and amyotrophic lateral sclerosis, also know as ALS or Lou Gehrig’s disease.

“This striking demonstration of a treatment that stems age-related cognitive decline in living animals points the way to potential development of the first cures that will address the core illness process in Alzheimer’s disease,” said Dr. Thomas Insel, director of the National Institute on Mental Health, which helped pay for the study.

http://www.dimebonalzheimers.com/

Dimebon Over Counter Treatment

One Hour Canada

Furnasman New Homes

Furnasman Winnipeg

  • Share/Bookmark
Blog Traffic Exchange Related Websites

UK Studies to Look at Alzheimer’s, Down Syndrome

Monday, July 12th, 2010

The University of Kentucky Sanders-Brown Center on Aging is looking for two groups of patients to help learn more about Alzheimer’s disease.

One study will examine how a new drug can supplement existing treatment; the other focuses on Down syndrome and Alzheimer’s.

The first study is looking at how the drug Dimebon can help Alzheimer’s patients already taking Aricept.

Because Alzheimer’s is a complex disease, patients sometimes need multiple drugs to address their symptoms, said Dr. Gregory Jicha, assistant professor of neurology at the UK College of Medicine. Aricept is one of the most widely prescribed Alzheimer’s drugs in the country.

Dimebon is thought to improve the mitochondrial function in brain cells, preventing damage. Cell parts called mitochondria are critical to brain function because they are the primary source of cells’ energy.

Aricept appears to enhance the brain’s concentration of acetylcholine, an enzyme crucial to memory and learning, he said.

Jicha said a good candidate for this study would have relatively mild symptoms. “In the early stage of the disease people can understand what the trial means and participate in the decision to help find better medicine and potential cures for Alzheimer’s,” he said.

The UK effort is part of an international project that will evaluate more than 1,000 patients, including at least a dozen at UK.

Another new research project looks at the connection between Down syndrome and Alzheimer’s. The $2.4 million, five-year study will look at how Down syndrome and Alzheimer’s disease may affect a person’s memory and thinking as they get older, said Dr. Elizabeth Head, who will lead the study.

The study will recruit and follow 40 people older than 35 with Down syndrome. In addition, 10 to 12 people with Down syndrome and Alzheimer’s disease will be recruited for a single research session.

The Down syndrome patients without Alzheimer’s will be tested every six months.

Head said the life expectancy of Down syndrome patients has increased dramatically over the years but the services they need as they age have not kept up. “There is really not a whole lot out there for them,” she said. “They are a little underserved.”

At the same time, she said, Down syndrome patients offer a unique opportunity to study Alzheimer’s. The chromosomal abnormality that creates Down syndrome also results in the overproduction of the protein that causes Alzheimer’s.

“They make a protein that causes Alzheimer’s disease. They are making too much of it from birth,” she said.

Most middle-age Down syndrome patients have full-blown Alzheimer’s disease in their brain but not all of them develop dementia, she said. Understanding how they continue to function could be key to helping others with Alzheimer’s, she said.

More than 400,000 people in the United States have Down syndrome. Overall, 50 percent of people with Down syndrome age 55 and older may have Alzheimer’s disease.

Overall, some 5.3 million in the United States have Alzheimer’s. According to the Alzheimer’s Association that number is expected to increase dramatically as the baby boomer generation continues to age.

Jicha said it’s possible if a patient isn’t right for one of these studies, several more are currently underway that might be a better fit.

“We always have a variety of opportunities,” he said. “Every study has a different number demands.”

“We are trying to build an army to fight Alzheimer’s,” he said. “That army doesn’t just include doctors and researchers but battalions of patients willing to pick up these new weapons to join the fight.”

Fort McMurray Auto Financing Online

Furnasman One Hour UV Lights

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Alzheimer's Test: When Should You Be Screened? Image via Wikipedia Alzheimer's test: when should you be screened? I was reminded recently of the dangers of Alzheimer's after passing my 54th birthday.  There was an ad with a...
  • Rising Blood Sugar Levels May Cause Brain Damage in Older People Rising blood sugar levels and brain damage in older people may be connected after all, according to new research. Scientists are reporting that rising blood levels may in fact be...
  • Being Fully Present We all have our own reality shaped by our current and past experiences. My perception is as real to me as another's is to them. This is true, but can...
  • Interesting Facts: Volume 1 [/caption] WORLD FACTS Who Made The Marree Man? facts 60 km out of the town of Marree in South Australia, there is the figure of a man etched into the...
  • Americans Not Listening to Music on Their Phones Forrester Research has completed an interesting bit of research that says that Americans are not listening to music on their cell phones like people in many other countries, despite years...
  • French scientists crack secrets of Mona Lisa [/caption] PARIS – The enigmatic smile remains a mystery, but French scientists say they have cracked a few secrets of the "Mona Lisa." French researchers studied seven of the Louvre...
  • Obama to announce new health benefits [/caption] WASHINGTON – President Barack Obama on Tuesday will announce new health insurance benefits for consumers, marking the first 90 days since he signed landmark legislation to expand coverage. The...

Job Cuts at Medivation

Friday, June 18th, 2010

Medivation, Inc. (MDVN) recently announced that it intends to reduce its workforce by 20% or 23 people to save costs and focus its resources towards research and developmentmag glass 10x10 Job Cuts at Medivation activities related to dimebon and MDV3100.

Medivation also announced the departure of its senior vice president of clinical development and the vice president of commercial development. The companymag glass 10x10 Job Cuts at Medivation said that it is no longer looking for a new Chief Financial Officer (CFO) as this post will be filled by the current Chief Business Officer (CBO).

Medivation’s workforce reduction announcement comes on the heels of disappointing phase III results reported earlier this month on its lead pipeline candidate, dimebon. Dimebon, which is being developed for Alzheimer’s disease in collaboration with Pfizer, Inc. (PFE), failed to achieve both its primary and secondary endpoints in a phase III study (CONNECTION).

Dimebon was the most advanced pipeline candidate at Medivation, which has no marketed products in its portfolio. The successful development of dimebon would have been a major boost for the company. In addition to the Alzheimer’s indication, Medivation is also studying dimebon for Huntington’s disease.

Going forward, Medivation intends to focus on the further analysis of the CONNECTION data, which will help determine future development plans for the candidate. Dimebon is currently being studied in combination with Pfizer’s Aricept for the treatment of mild-to-moderate Alzheimer’s. Positive results from this study could allow the companies to push for approval of the product as a combination therapy.

Dimebon is also in another study which is being conducted in Huntington disease patients.

We currently have a Neutral recommendation on Medivation. The high profile phase III failure was a major setback for the company. Medivation could suffer another blow if Pfizer decides to pull out from the collaboration agreement for dimebon.

We note that Pfizer already has another Alzheimer’s candidate, bapineuzumab, in its portfolio that is being developed with Elan Corp (ELN) and Johnson & Johnson (JNJ). As such, Pfizer may decide to focus its efforts towards the development of bapineuzumab.

21 Degrees One Hour

Mr Furnaces One Hour

Boonstraonehour

Dimebon Online

http://www.dimebonalzheimers.com/

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Aricept

Friday, October 23rd, 2009

Aricept (Donepezil), is a centrally acting reversible acetyl cholinesterase inhibitor. Its main therapeutic use is in the treatment of Alzheimer‘s disease where it is used to increase cortical acetylcholine. Donepezil is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, donepezil’s effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact.

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Study: Stem Cells Fight Multiple Sclerosis The symptoms of multiple sclerosis could be reversed thanks to stem cell transplants from the patient’s own bone marrow, according to a study that will be published in March in...
  • How to Find the Right Golf Shoes Having the right pair of golf shoes impacts much more than your comfort level. If you’re wearing the wrong shoes or if they do not fit properly, this can effect...
  • EarthTalk: On Leaching Plastics For Food Storage. EarthTalk is a weekly installment from E/The Environmental Magazine. Dear EarthTalk: I’ve read that plastic bottles are not always safe to reuse over and over as harmful chemicals can leach...
  • MonaVie and the Placebo Effect There are times where people will give a testimony that MonaVie helped them with [medical condition X]. I assert that it is really impossible to tell if MonaVie did that...
  • Whole Vs Processed Foods Most people know that a whole food diet costs more and wonder whether it's worth paying the extra money. Whole foods are foods that are unprocessed or processed as little...
  • Florida Woman with Lung Disease (COPD) Off Oxygen After Adult Stem Cell Therapy Thanks to stem cell research, a Florida female smoker, Barbara Mckean who was on oxygen 24 hours per day before stem cell therapy using her own Adult Stem Cells is...
  • Butter vs. Margarine - Who's The Bad Guy? Food can be confusing! What's good for you one day is labeled bad the next - or visa versa. Take butter, for instance. In the past, it was branded an...

Additional Sources New Upcoming Medications Alzheimer's Arena – Financial Analysts

Wednesday, August 26th, 2009

Pfizer and the Japanese drug maker Eisai, currently co-market Aricept, the leading Alzheimer’s drug today with worldwide sales of more than $2 billion.

But Aricept loses patent protection at the end of next year, which is one reason why Pfizer has decided to invest heavily in new Alzheimer’s drug research.
Last September, Pfizer acquired worldwide commercial rights to Dimebon, an experimental Alzheimer’s drug currently in phase III studies. Pfizer paid Medivation(MDVN Quote), Dimebon’s owner, $225 million upfront for the rights, making it one of the largest drug partnership deals of 2008.

Pfizer also has four Alzheimer’s drugs in its own pipeline, most of which are in the early stages of clinical trials. This includes an experimental Alzheimer’s drug acquired in 2006 when Pfizer bought privately held Rinat Neuroscience.

Wyeth has 10 Alzheimer’s drugs in clinical trials, both internally and through partnerships, the most important of which is with Irish drug maker Elan(ELN Quote). The two companies share development efforts and marketing rights to bapineuzumab, which is being studied in four phase III clinical trials.

If the acquisition of Wyeth announced Monday closes as is, Pfizer would boost its Alzheimer’s drug pipeline from five drugs in clinical trials to 15, including two of the four drugs currently in pivotal phase III studies. (Eli Lilly(LLY Quote) and Baxter(BAX Quote) own the other two phase III Alzheimer’s drugs.)

Any new drug that could potentially stop or even reverse the loss of memory or cognitive decline that makes Alzheimer’s such a devastating disease would be a mega-blockbuster. Actual sales estimates vary and are conditional on the efficacy and safety profile of the drug, but it’s not out of bounds to forecast a groundbreaking Alzheimer’s drug achieving peak sales of well over $10 billion, perhaps even $20 billion a year.

More on PFE ‘Fast Money’ Portfolios of the WeekStock Wrap: The Real Story, August 5Mad About Options: Keeping Healthy With BaxterPfizer Prescribes SustainabilityDollar Drops as Risk Appetite GrowsToday’s Outrage: Bemoaning the ‘Strong’ DollarWyeth Lifts ’09 Forecast as Earnings GainPfizer’s Blah Quarter Points to Wyeth DealDividend.com: Midday PlaybookCramer’s Take on Headline Stocks Market Activity Elan Corporation PLC| ELN UPEli Lilly & Company| LLY UPPfizer’s cholesterol drug Lipitor, with $13 billion a year in sales, loses patent protection in 2011. If Pfizer were to hit it big with a groundbreaking Alzheimer’s drug, the company and its investors would find it a lot easier to forget about lost Lipitor sales.
Before Pfizer can start counting new Alzheimer’s revenue, the company faces a host of challenges, not the least of which is waiting to see how many, if any, of these experimental Alzheimer’s drugs will actually wind up working.

Even before that, Pfizer could face scrutiny from the Federal Trade Commission, owing to potential antitrust issues arising from amassing such a large portfolio of Alzheimer’s drugs. This could lead to Pfizer having to divest some of its Alzheimer’s assets, says Jack Walsh, a commercial litigator with the law firm Lathrop & Gage in St. Louis, Mo.

Pfizer spokesman Jack Cox said, “We can’t speculate on the actions of regulators, but we recognize that this is a large, complex transaction. We will work closely with the regulatory bodies to obtain the necessary clearances.”

And Pfizer may have a tricky time managing relationships with its two main Alzheimer’s partners – Medivation and Elan — both of which will want to be seen as a priority over the other when it comes to Pfizer’s time and financial commitment.

More on PFE ‘Fast Money’ Portfolios of the WeekStock Wrap: The Real Story, August 5Mad About Options: Keeping Healthy With BaxterPfizer Prescribes SustainabilityDollar Drops as Risk Appetite GrowsToday’s Outrage: Bemoaning the ‘Strong’ DollarWyeth Lifts ’09 Forecast as Earnings GainPfizer’s Blah Quarter Points to Wyeth DealDividend.com: Midday PlaybookCramer’s Take on Headline Stocks Market Activity Elan Corporation PLC| ELN UPEli Lilly & Company| LLY UPPfizer singled out bapineuzumab in its press release discussing the Wyeth acquisition and also talked about the importance of the drug and Alzheimer’s, in general, on its Monday conference calls.
Corey Davis, drug analyst at Natixis Bleichroeder, says this was likely Pfizer trying to ease any misgivings Elan may have, especially given Pfizer’s existing commitment to Medivation.

“The fact that Pfizer specifically talked about bapineuzumab was probably a signal to Elan that Pfizer intends to maintain Wyeth’s investment in the drug,” said Davis, who covers Elan with a buy rating.

But if Pfizer was sending the love to Elan on Monday, it wasn’t necessarily reciprocated.

Elan spokeswoman Mary Stutts said the company expects a federal antitrust review of the Pfizer-Wyeth deal, particularly in terms of the Alzheimer’s assets, and that until that review is completed, Elan is taking a wait and see attitude.

“We cannot assume at this point that Pfizer will be Elan’s partner for bapineuzumab,” said Stutts.

She added that the current contract between Elan and Wyeth for bapineuzumab and a second Alzheimer’s drug, ACC-001, does include change of control provisions. Stutts would not elaborate on the details of those provisions.

Doug Petkus, a spokesman for Wyeth, said the focus of both Wyeth and Pfizer continues to be on Alzheimer’s research, including bapineuzumab, but he would not say what ultimately happens to the relationship with Elan if and when Pfizer acquires Wyeth.

Data from a phase II study of bapineuzumab, presented last year, raised doubts about the drug’s efficacy and safety. While Elan has moved aggressively to enroll patients in two U.S.-based phase III clinical trials, Wyeth has had problems enrolling patients in two international studies due to safety concerns raised primarily by regulators in Europe.

Natixis analyst Davis believes there is little chance that Pfizer will decide to drop bapineuzumab altogether. “The phase III studies are pretty much on auto-pilot now, so I don’t think Pfizer has much incentive to make major changes.”

Medivation CEO David Hung says his company’s partnership with Pfizer remains unchanged.

“We have not been told of any changes, so I assume that we’re on track. The partnership [for Dimebon] has gone very well and Pfizer speaks enthusiastically about the drug. Alzheimer’s is definitely an area where Pfizer is committed to investing a lot of resources.”

http://www.thestreet.com/story/10460064/1/pfizer-gamles-on-building-alzheimers-empire.html?cm_ven=GOOGLEFI

Dimebon Alzheimer’s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites

Donepezil

Monday, April 20th, 2009

Donepezil (Aricept)  is a drug derived from components of actual black pepper.  It is the most widely prescribed drug for patients who have Alzheimer’s disease .  It works by preventing the breakdown of the chemical neurotransmitter acetylcholine in the brain.  The tablet is taken once daily , which helps with regular pill taking  ( compliance).  It seems that for all the studies that have been done in an effort to improve the taking of pills and medications on a regular basis – that is compliance – that lack of compliance is generally estimated at a full 50 %.   The only things that seem to enhance and improve compliance levels with medications are 1) to reduce the frequency of dosage and 2) tie in the pill taking to a regime involving a daily habit — 0ften meals.   To make matters perhaps more amusing and even worse it seems that patients often improve their regular pill taking and compliance of medications when they become more ill and are reminded of their symptoms.  The poor health care providers are often at a loss to explain symptoms and side effects that often and usually were not present before and are the direct result of patients now taking their pills and medications on a regular and proper basis. On top of that multi-drug side effects and interactions may now emerge since the patient may well be finally taking the drugs they had forgot to or had chosen not to take before in their treatment plan and plans.

Forteo, Enbrel, Methotrexate, Folic Acid, Donepezil Hcl … – Large, long term drug study: Forteo, Enbrel, Methotrexate, Folic Acid, Donepezil Hcl, Hydrocodone Bitartrate And Acetaminophen, Acetylsalicylic Acid Srt drug interactions and effectivenesses for females and males at all ages (2742948)

Phase 3 study of Dimebon and donepezil combination therapy for … – Pfizer and Medivation, Inc announced the initiation of a 12-month, Phase 3 trial of the investigational drug Dimebon in combination with donepezil HCl for the treatment of mild-to-moderate Alzheimer’s disease (AD).

Alzheimer’s Reading Room: Dimebon Added to Donepezil in Patients … – The study builds on data from a small-scale safety and tolerability trial of Dimebon added to donepezil, which found the combination to be well tolerated. CONCERT is designed to complement previous and ongoing studies by further …

Pfizer and Medivation Initiate Phase 3 Trial of Dimebon Added to … – New 12-month study broadens Phase 3 clinical program to further eval… …NEW YORK and SAN FRANCISCO April 15 /- Pfizer … …,Pfizer,and,Medivation,Initiate,Phase,3,Trial,of,Dimebon,Added,to,Donepezil,in,Patients,with,Alzheimer’s …

Drug interactions analysis of Zyprexa, Venlafaxine Hcl … – Real world drug safety study: Drug interactions analysis of Zyprexa, Venlafaxine Hcl, Risperidone, Quetiapine, Donepezil Hcl (2704001) … Donepezil Hcl. ^Back to Content. 2 related incidents are studied for males aged 75 (±5): …

Donepezil – Welcome to donepezil WebLog donepezil BUY ONLINE! Related Posts: {RELATED}. EPIX Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing novel therapeutics through the use of its proprietary and highly …

Donepezil – Darkover has butorphanol opiate withdrawal features once crooning under heal children fulvicin always said smoke from trigger breathing relenza market share gsk hat about with all too was aricept donepezil hydrochloride omilla and …

Donepezil Hcl side effects and drug interactions analysis (ID … – Drug(s): Donepezil Hcl Date: Aug, 28, 2008 Patient demographics: unspecified year(s) old Male who has Cognitive Disorder.

 

The Donepezil comes in tablet form.   The typical daily dose id 10 mg. It is generally well tolerated.  Often the dose is started low at 5 mg per a day and then “bumped” up to the 10 mg dose.    Some authorities and practitioners in the field have believed that the drug will only work for a six month time period whereas others have continued treatment with the drug and made substantiated claims that a beneficial effect can be demonstrated in Alzheimer’s patients for several years. Indeed the medication may have  a disease modifying and limited beneficial effect all on its own.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Doubt Cast on New Alzheimer's Drugs  Do the new Alzheimer's drugs really work?Apparently not, according to some recent Italian studies.Three drugs, Aricept, Exelon, and Reminyl are being prescribed to patients who are in the  mild to...
  • A U.S. Supreme Court Justice Speaks on Behalf of Alzheimer's Patients Families and caregivers of Alzheimer's patients have a strong ally  in retired U.S. Supreme Court Justice Sandra Day O'Conner. Her husband John has Alzheimer's and she understands the difficulties of caregiving ...
  • Oral diabetes drug, Avandia, may greatly increase risk of heart attack Patients taking Avandia, an oral diabetes drug from GlaxoSmithKline, proved 43 percent more likely to have heart attacks according to a recent study published in the New England Journal of...
  • Review: If I'm So Smart, Why Can't I Lose Weight? - Tools to Get it Done According to Brooke Castillo, author of this book, intelligent and accomplished men and women often have intense difficulty losing weight and getting healthy. One of the main reasons that it...
  • Save Money on Medicine [/caption]I haven't mentioned it in a long-time, but in former life (we are going back to my high school and college years), I was a pharmacy technician. I found it...
  • Manny and Brett It was a great sports day for me. Two of my least favorite sports figures made the news. The twice retired quarterback Brett Favre told my Minnesota Vikings that he...
  • OnPar Golf Touchscreen GPS User Reviews Send this to a friend OnPar Golf Touchscreen GPS Manufacturer: OnPar Customer Rating: List Price: $479.95 Sale Price: $319.99 Availibility: Usually ships in 1-2 business days Buy Now...

Cholinesterase Inhibitors – Their Use and Withdrawl of Treatment

Sunday, April 19th, 2009

The cholinteresterase inhibitors thus far available  are currently only approved by the F.D.A. (The US Food and Drug Administration)  , are approved by the FDA as only being effective for Alzherimer patients who have thus far mild to moderate disease.  However these drugs and medications – that is the cholinesterase classification medication grouping, may well show promise for those who are in the earliest as well as later stages of the disease , as well.  In addition they could well be of benefit and benefits to those with mil cognitive impairment as well.

One large study evaluated the use of Aricept (dozepezil) in the treatment of mild cognitive  impairment and found that it significantly reduced conversion to active Alzheimer’s progressive disease.

Current Treatment for Alzheimer’s Disease – Prescription cholinesterase inhibitors include Exelon and Aricept. These drugs have varying side effects and can have contraindications with other medication, so it can be difficult for doctors to find the right pharmaceutical match and …

Methods and compositions using cholinesterase inhibitors – The invention provides methods for treating and/or preventing Alzheimer’s disease, psychiatric illnesses, encephalitis, meningitis, fetal alcohol syndrome, Karsakoff’s syndrome, anoxic brain injury, cardiopulmonary resuscitation …

alzheimer disease – These drugs are called cholinesterase inhibitors because they inhibit the enzymes that break down acetylcholine (acetylcholinesterase and butyrylcholinesterase). Some drugs target only acetylcholinesterase, whereas some target both …

Galantamine: Welsh daffodils containing galantamine may help fight … – Galantamine is a competitive and reversible cholinesterase inhibitor. It is believed it works by enhancing cholinergic function by increasing the concentration of acetylcholine in the brain. The atomics resolution 3D structure of the …

Cholinesterase Inhibitors Reduce Aggression, Wandering And … – Cholinesterase Inhibitors Reduce Aggression, Wandering And Paranoia In Alzheimer’s Disease.

While cholinesterase inhibitors are now believed to he most helpful in persons with severe Alzheimer’s disease ,sometimes patients can be maintained on these classes and classifications of drugs indefinitely due to the fact and observation that in clinical practice , that often patients who stop taking these drugs or types of medications deteriorate rapidly when the drugs are arbitrarily stopped or withdrawn.  Indeed there is new and upcoming evidence from studies that suggest that stopping cholinesterase inhibitors will result in decline in functioning to a level that the patient would have been at it they – he or she – had not been taking the drug in the first place.

In addition drugs in this class appear to have an added benefit in improving behaviour as well as overall cognitive abilities.

Dimebon Alzheimer?s Disease

PS3 Mod Chips

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Depression Risk Factors for Women There are a number of ailments that women are actually at risk for developing without actually realizing it. For example, heart disease risk factors for women are much more significant...
  • Common Bipolar Disorder Treatments When someone is diagnosed with Bipolar, there are two types of treatments available. These treatments are called: pharmacological and psychotherapeutic. They usually will work so long as the person is...
  • Newest Stem Cell Treatment for Blindness British scientists have reportedly perfected the technique for curing macular-degeneration related blindness with adult stem cells. Returning Hope, a pioneering Asian adult stem cell treatment portal, expects to be one...
  • Heart Disease Risk Factors for Women There are a number of ailments that women are actually at risk for developing without actually realizing it. For example, heart disease risk factors for women are much more significant...
  • Stem cell treatment gives hope to Crohn's disease sufferers Image via Wikipedia Sufferers from the debilitating bowel condition Crohn's disease may be cured using a groundbreaking stem cell treatment, according to the British doctor leading the research. Initial findings...

Cholinesterase Inhibitors in the Treatment of Alzheimer's Disease

Friday, April 17th, 2009

Perhaps the most prescribed category of drugs for Alzhimer’s disease are the “Cholinesterase Inhibitor”  branch.  This group and grouping includes four medications.  Their trade names are “Aricept” , “Cognex” , “Excelon”  and “Reminyl”.  This group of medications , specifically the  “Cholinterase Inhibitors”   work via a mechanism of raising brain levels of the chemical neurotransmitter in the brain , acetylcholine , that is deficient in people and patients who exhibit the signs , symptoms and progression of Alzheimer’s Disease and its variants.

It can be said that overall these drugs , and this classification of medications , work to slow the progression of Alzheimer’s Disease.

In terms of side effects , and the range and variations of side effects with the Cholinesterase classification of drugs  side effects are all pretty similar in their type and range.  This generally includes , nausea , vomiting ,diarrhea , stomach pain, and loss of appetite.  However care must be exhibited with the drug / medication Cognex which can work to effect and cause liver toxicity and toxicities.

Dimebon Alzheimer?s Disease

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites
  • Daily supplements for the aging While you should consult with a physician before undertaking radical changes to your diet or vitamin and supplement intake, we've listed here a few supplements that have become staples on...
  • The Physical Side Effects of Debt Anyone who has carried a heavy load of debt is keenly aware of its ability to strain your budget and your relationships, but is it possible that being deep in...
  • Book Review: Survival of the Sickest I spent Sunday evening browsing books at Barnes and Nobles. I picked up The Future for Investors: Why the Tried and the True Triumph Over the Bold and the New...
  • 4 Foods to Lower Your Blood Pressure High blood pressure is a problem that affects millions of Americans every year. Many of us are struggling with numbers that are too high and we cannot seem to get...
  • Top 10 Most Dangerous Sleep Apnea Side Effects [/caption] This article will highlight top 10 dangerous sleep apnea side effects your body might be experiencing and why it’s so important to look for sleep apnea cure no matter...
  • Viagra - The Legal Performance Enhancing Drug Every time I turn on ESPN, I hear something about performance enhancing drugs. Typically, it's something about some Senator wasting millions of tax payer's dollars investigating whether or not some...
  • Adult stem cells therapy for urine incontinence in women The past few years brought high development in obtaining and culturing autologous adult stem cells. In this paper we review publications of experimental investigations and clinical trials of the muscle-derived...

Side Effects Dosage of Razadyne fro Alzheimer's

Monday, February 16th, 2009

Advantages of Razadyne ( galantamine) include that it may not as much disturb sleep and the sleep process in Alzheimer’s patients as the other mainstay medication of treatment of Alzheimer’s Aricept.

Common side effects of Razadyne include possible nausea , vomiting ,diarrhea ,fainting , loss of appetite and weight loss.? Most of these are mild and tend to subside as the body learns to adjust to the medication over time.

In M.C.I. trials Razadyne , thirteen ( 13) Razadyne recipients died, compared to only a single ( one) death among placebo patients – a finding that it seems of not many doctors are aware of.? Because more deaths occurred in the Razadyne group , than in the placebo group, doctors cannot rule out that the deaths were somehow related or due to Razadyne therapy.

Razadyne therapy can be initiated for patients with mild or moderate Alzheimer’s disease.

Dosage:? Razadyne? is supplied in both regular and extended release forms. Razadyne ER ( or SR designation slow- release formulation), can be taken once a day whereas Razadyne immediate release formulations are taken on a twice a da regime.? The two different formulations of Razadyne – immediate release and slow extended or sustained release formulations should not be taken together at the same time.? Its either one or the other since the active medication ingredient is the same.

The effective dose of Razadyne Extended Release (ER)? as well as immediate release ( regular) Razadyne? is stated to be in the ranges of 16 to 24 milligrams a day.? Doctors usually recommend starting with a lower initial dose of 8 milligrams a day and then increasing it to the lower maintenance dosage of 16 mg over a time span period of four ( 4) weeks. Then up according to the specific patients requirements and needs over a time span the dosage can be increased to upper stated limits of the drug.? Often patients can tolerate medications at higher levels if first started on a much lower initial dose and the dosage increased slowly over time.? The maxim is start lower and increase dosage slowly over time.

To reduce side effects , in terms of sleep disturbances and insomnia it is especially recommended to take the medication in the morning time with the extended release ER / SR form , and the taking of the second dose of the immediate release form somewhat earlier during the 24 clock of the daytime rather than later.

Dimebon Alzheimer?s Disease

http://www.psychiatry.co.il/

????????-?”? ???? ?? ???, ????? ?????????,????????? ??????

http://www.dimebonalzheimers.com

  • Share/Bookmark
Blog Traffic Exchange Related Websites